Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 an… Read more
Yifan Xinfu Pharmaceutical Co Ltd (002019) - Total Assets
Latest total assets as of September 2025: CN¥13.11 Billion CNY
Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) holds total assets worth CN¥13.11 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yifan Xinfu Pharmaceutical Co Ltd - Total Assets Trend (2001–2024)
This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Yifan Xinfu Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Yifan Xinfu Pharmaceutical Co Ltd's total assets of CN¥13.11 Billion consist of 30.8% current assets and 69.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.2% |
| Accounts Receivable | CN¥1.60 Billion | 13.0% |
| Inventory | CN¥1.06 Billion | 8.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.57 Billion | 20.9% |
| Goodwill | CN¥2.74 Billion | 22.3% |
Asset Composition Trend (2001–2024)
This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yifan Xinfu Pharmaceutical Co Ltd's current assets represent 30.8% of total assets in 2024, a decrease from 51.8% in 2001.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2024, down from 16.2% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 1.0% in 2001.
- Asset Diversification: The largest asset category is goodwill at 22.3% of total assets.
Yifan Xinfu Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Yifan Xinfu Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Yifan Xinfu Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Yifan Xinfu Pharmaceutical Co Ltd generates 0.42x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Yifan Xinfu Pharmaceutical Co Ltd generates $ 3.14 in net profit.
Yifan Xinfu Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.32 | 1.65 |
| Quick Ratio | 0.87 | 0.96 | 1.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥912.33 Million | CN¥ 942.35 Million | CN¥ 1.38 Billion |
Yifan Xinfu Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Yifan Xinfu Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.78 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | 6.8% |
| Total Assets | CN¥12.29 Billion |
| Market Capitalization | $1.03 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Yifan Xinfu Pharmaceutical Co Ltd's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yifan Xinfu Pharmaceutical Co Ltd's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yifan Xinfu Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual total assets of Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥12.29 Billion | +6.84% |
| 2023-12-31 | CN¥11.50 Billion | -8.32% |
| 2022-12-31 | CN¥12.54 Billion | +3.11% |
| 2021-12-31 | CN¥12.17 Billion | +4.54% |
| 2020-12-31 | CN¥11.64 Billion | +5.16% |
| 2019-12-31 | CN¥11.07 Billion | +13.21% |
| 2018-12-31 | CN¥9.77 Billion | +11.49% |
| 2017-12-31 | CN¥8.77 Billion | +25.55% |
| 2016-12-31 | CN¥6.98 Billion | +53.59% |
| 2015-12-31 | CN¥4.55 Billion | +36.35% |
| 2014-12-31 | CN¥3.33 Billion | +214.30% |
| 2013-12-31 | CN¥1.06 Billion | -0.05% |
| 2012-12-31 | CN¥1.06 Billion | -8.98% |
| 2011-12-31 | CN¥1.17 Billion | -2.93% |
| 2010-12-31 | CN¥1.20 Billion | +5.35% |
| 2009-12-31 | CN¥1.14 Billion | +33.19% |
| 2008-12-31 | CN¥856.27 Million | -3.18% |
| 2007-12-31 | CN¥884.42 Million | +51.87% |
| 2006-12-31 | CN¥582.36 Million | +12.65% |
| 2005-12-31 | CN¥516.94 Million | +44.12% |
| 2004-12-31 | CN¥358.70 Million | +80.22% |
| 2003-12-31 | CN¥199.04 Million | +50.83% |
| 2002-12-31 | CN¥131.96 Million | +51.04% |
| 2001-12-31 | CN¥87.37 Million | -- |